Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic
Omega Funds and Abingworth teamed up to lead an $88 million round for Spruce, which is primarily focused on developing tildacerfont to treat classic congenital adrenal hyperplasia.
The data they came up with was based on patients who lack enzyme 21-hydroxylase, which throws a monkey wrench in the production of cortisol while increasing production of male sex hormones to dangerous levels. Their drug — a CRF-1 receptor antagonist — targets ACTH and a downstream biomarker dubbed A4, and in the Phase IIa investigators tracked a mean reduction of 74% for ACTH, 82% for 17-OHP and 55% for A4.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
